ストックスクリーナーアプリを入手
0.295
6.23%
-0.0196
Revelation Biosciences Inc (REVB) 最新ニュース
Revelation Biosciences stock hits 52-week low at $0.32 - Investing.com
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Revelation Biosciences files for secondary offering of common stock - MSN
Revelation Biosciences stock hits 52-week low at $0.42 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.42 By Investing.com - Investing.com UK
Reviewing Emmaus Life Sciences (OTCMKTS:EMMA) and Revelation Biosciences (NASDAQ:REVB) - Defense World
Revelation Biosciences stock hits 52-week low at $0.7 By Investing.com - Investing.com South Africa
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.7 - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.17% - Investing.com UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Revelation Biosciences Secures $4M Through Warrant Exercise, Issues New Warrants - StockTitan
FDA approves Revelation Biosciences' drug trial for CKD By Investing.com - Investing.com Nigeria
Best Penny Stocks for Today (Charts Updated Daily) - Benzinga
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND - Marketscreener.com
FDA approves Revelation Biosciences' drug trial for CKD - Investing.com
Revelation Bio's Kidney Disease Drug Gemini Receives FDA IND Approval for Phase 1b Trial - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Warning: REVB is at high risk of performing badly - MSN
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - BioSpace
Revelation Bio Achieves Key Manufacturing Milestone for Kidney Disease Drug Trial | REVB Stock News - StockTitan
United Therapeutics (UTHR) Stock Dips Amid Broader Biotech Indus - GuruFocus.com
Allergic Rhinitis Treatment Market Size in the 7MM is expected to Grow by 2034 | DelveInsight - Barchart
REVB: Good Expense Control as Company Prepares for Trials - Research Tree
Pre-market Movers: REVB, CDIO, SMLR, DWTX... - RTTNews
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket - Benzinga
REVB Results Set Stage for Future Growth - Yahoo Finance
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - sharewise
Revelation Biosciences Inc expected to post a loss of $2.29 a shareEarnings Preview - XM
Revelation Bio Q3 Loss Narrows to $2.2M, Secures $3.8M from Warrants Amid Cash Decline | REVB Stock News - StockTitan
Revelation Biosciences Inc (REVB) Quarterly 10-Q Report - Quartzy
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India
United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News
Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle
Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat
A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News
Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch
Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex
Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha
Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World
Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia
Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada
Revolution Medicines COO sells over $191k in company stock By Investing.com - Investing.com Canada
Revolution Medicines CFO sells over $99k in company stock - Investing.com India
Revolution Medicines executive sells over $200k in company stock - Investing.com
Revolution Medicines general counsel sells shares worth over $64k By Investing.com - Investing.com UK
Renovaro faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia
The growth track for Revolution Medicines Inc (RVMD) has changed recently - SETE News
Crown Labs tender offer for Revance delayed, expect deal to be completedanalyst - MSN
Revelation Pharma Announces Revelation Wholesale, an Extension of Its National Compounding Network - PR Newswire
455,099 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Sofinnova Investments Inc. - MarketBeat
Revolve Group (NYSE:RVLV) Trading Down 5.2% - MarketBeat
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):